Low tumor cell density environment yields survival advantage of tumor cells exposed to MTX in vitro.
Stable resistance to methotrexate has been well characterized after prolonged treatment of the HT-29 colon cancer cell line, but the mechanism of cell survival at the early stages of the drug resistance process still remains unclear. Here, we demonstrate that human cancer cells in vitro are sensitive to methotrexate only above a critical cell culture density, which specifically coincides with their ability to deplete the extracellular nucleosides from a fully supplemented culture medium. At lower cell densities, extracellular nucleosides remain intact and allow salvage nucleotide synthesis that renders cells insensitive to the drug. Consistently, medium conditioned by cells seeded at standard cell densities sensitizes low cell density cultures. Extracellular nucleosides are the determinants of sensitivity because the latter effect can be mimicked with the use of inhibitors of nucleoside cellular import and reversed by supplying exogenous thymidine and hypoxanthine. Interestingly, treatment at a sensitizing cell density does not preclude the survival of less than 1% of the cells--which have no intrinsic resistance--owing to the inability of the dying cell population to condition the culture medium; this population thus survives indefinitely to continuous treatment by keeping adapted to a low cell number. This cell density-dependent adaptive process accounts for the initial steps of in vitro resistance to methotrexate (MTX) and provides a novel mechanistic insight into the cell population dynamics of cell survival and cell death during drug treatment.
de Anta
Josep M
JM
Unitat de Biologia Cellular i Molecular, Institut Municipal d'Investigació Mèdica, C/Dr. Aiguader, 80, 08003, Barcelona, Spain.
Real
Francisco X
FX
Mayol
Xavier
X
D000222:Adaptation, Physiological; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D019073:HT29 Cells; D006801:Humans; D008727:Methotrexate / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012516:Osteosarcoma / Q000188:drug therapy / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate